Genetic Basis of Dyslexia

Dyslexia is a learning disorder that has a significant genetic component, with heritability estimated to be between 54% and 84%. Recent studies have identified nine specific genetic loci associated with dyslexia, labeled as DYX1 to DYX9. These loci are located on various chromosomes, with DYX1 on chromosome 15 at location 15q21.3, DYX2 and DYX4 on chromosome 6, DYX3 on chromosome 2, DYX5 on chromosome 3, DYX6 on chromosome 18, DYX7 on chromosome 11, DYX8 on chromosome 1, and DYX9 on Xq27.3. These findings provide important insights into the genetic basis of dyslexia and may lead to improved diagnosis and treatment options in the future.

Tricyclic Antidepressants: Uses, Types, and Side-Effects

Tricyclic antidepressants (TCAs) are a type of medication used for depression and neuropathic pain. However, due to their side-effects and toxicity in overdose, they are not commonly used for depression anymore. TCAs can be divided into two types: first generation (tertiary amines) and second generation (secondary amines). The secondary amines have a lower side effect profile and act primarily on noradrenaline, while the tertiary amines boost serotonin and noradrenaline.

Some examples of secondary amines include desipramine, nortriptyline, protriptyline, and amoxapine. Examples of tertiary amines include amitriptyline, lofepramine, imipramine, clomipramine, dosulepin (dothiepin), doxepin, trimipramine, and butriptyline. Common side-effects of TCAs include drowsiness, dry mouth, blurred vision, constipation, and urinary retention.

Low-dose amitriptyline is commonly used for neuropathic pain and prophylaxis of headache. Lofepramine has a lower incidence of toxicity in overdose. However, amitriptyline and dosulepin (dothiepin) are considered the most dangerous in overdose. It is important to consult with a healthcare provider before taking any medication and to follow their instructions carefully.

When a patient’s mania becomes intractable and is accompanied by severe depression and catatonia, electroconvulsive therapy (ECT) may be necessary. Despite being treated with a combination of mood stabilizers, antipsychotic medication, and a short-acting benzodiazepine, this patient has not responded to treatment and has deteriorated to the point of requiring seclusion. This suggests that the mania is treatment-resistant and requires ECT.

Under section 58a of the Mental Health Act, there are safeguards in place to ensure that the patient’s capacity and consent are assessed before administering ECT. However, in cases where immediate action is necessary to prevent death of serious deterioration in mental health, ECT can be given without the patient’s consent under Section 62. In this case, the patient will receive ECT while awaiting a SOAD.

Subtle impairments of motor or sensory function that are not specific to a particular neurological condition and are referred to as neurological ‘soft’ signs. These signs are prevalent in individuals with schizophrenia and may serve as a potential endophenotype.

The Geriatric Mental State Schedule (GMSS) is a tool utilized to detect signs of depression among older adults.

In psychiatry, various questionnaires and interviews are used to assess different conditions and areas. It is important for candidates to know whether certain assessment tools are self-rated of require clinical assistance. The table provided by the college lists some of the commonly used assessment tools and indicates whether they are self-rated of clinician-rated. For example, the HAMD and MADRS are clinician-rated scales used to assess the severity of depression, while the GDS is a self-rated scale used to screen for depression in the elderly. The YMRS is a clinician-rated scale used to assess the severity of mania in patients with bipolar disorder, while the Y-BOCS is used to measure both the severity of OCD and the response to treatment. The GAF provides a single measure of global functioning, while the CGI requires the clinician to rate the severity of the patient’s illness at the time of assessment. The CAMDEX is a tool developed to assist in the early diagnosis and measurement of dementia in the elderly.

Norepinephrine: Synthesis, Release, and Breakdown

Norepinephrine is synthesized from tyrosine through a series of enzymatic reactions. The first step involves the conversion of tyrosine to L-DOPA by tyrosine hydroxylase. L-DOPA is then converted to dopamine by DOPA decarboxylase. Dopamine is further converted to norepinephrine by dopamine beta-hydroxylase. Finally, norepinephrine is converted to epinephrine by phenylethanolamine-N-methyltransferase.

The primary site of norepinephrine release is the locus coeruleus, also known as the blue spot, which is located in the pons. Once released, norepinephrine is broken down by two enzymes: catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). These enzymes play a crucial role in regulating the levels of norepinephrine in the body.

Nissl substance is composed of rough endoplasmic reticulum with free ribosomes and is responsible for synthesizing proteins. The Golgi apparatus modifies, organizes, and packages macromolecules for either secretion of internal use. Mitochondria are involved in producing energy for the cell. Microfilaments and microtubules provide structural support and aid in transportation within the cell. Lysosomes are spherical structures that contain digestive enzymes, which break down cellular waste and protect against threats such as viruses.

The Function of Proteasomes in Protein Degradation

Proteasomes play a crucial role in breaking down proteins that are produced within the cell. These cylindrical complexes are present in both the nucleus and cytoplasm of the cell. The process of protein degradation involves the tagging of proteins with a small protein called ubiquitin. The proteasome consists of a core structure made up of four stacked rings surrounding a central pore. Each ring is composed of seven individual proteins. This structure allows for the efficient degradation of proteins, ensuring that the cell can maintain proper protein levels and function.

A thyroid function test would confirm a diagnosis of hypothyroidism based on the patient’s medical history and symptoms.

Lithium – Pharmacology

Pharmacokinetics:
Lithium salts are rapidly absorbed following oral administration and are almost exclusively excreted by the kidneys unchanged. Blood samples for lithium should be taken 12 hours post-dose.

Ebstein’s:
Ebstein’s anomaly is a congenital malformation consisting of a prolapse of the tricuspid valve into the right ventricle. It occurs in 1:20,000 of the general population. Initial data suggested it was more common in those using lithium but this had not held to be true.

Contraindications:
Addison’s disease, Brugada syndrome, cardiac disease associated with rhythm disorders, clinically significant renal impairment, untreated of untreatable hypothyroidism, low sodium levels.

Side-effects:
Common side effects include nausea, tremor, polyuria/polydipsia, rash/dermatitis, blurred vision, dizziness, decreased appetite, drowsiness, metallic taste, and diarrhea. Side-effects are often dose-related.

Long-term use is associated with hypothyroidism, hyperthyroidism, hypercalcemia/hyperparathyroidism, irreversible nephrogenic diabetes insipidus, and reduced GFR.

Lithium-induced diabetes insipidus:
Treatment options include stopping lithium (if feasible), keeping levels within 0.4-0.8 mmol/L, once-daily dose of the drug taken at bedtime, amiloride, thiazide diuretics, indomethacin, and desmopressin.

Toxicity:
Lithium salts have a narrow therapeutic/toxic ratio. Risk factors for lithium toxicity include drugs altering renal function, decreased circulating volume, infections, fever, decreased oral intake of water, renal insufficiency, and nephrogenic diabetes insipidus. Features of lithium toxicity include GI symptoms and neuro symptoms.

Pre-prescribing:
Before prescribing lithium, renal function, cardiac function, thyroid function, FBC, and BMI should be checked. Women of childbearing age should be advised regarding contraception, and information about toxicity should be provided.

Monitoring:
Lithium blood levels should be checked weekly until stable, and then every 3-6 months once stable. Thyroid and renal function should be checked every 6 months. Patients should be issued with an information booklet, alert card, and record book.

Extrapyramidal side-effects (EPSE’s) are a group of side effects that affect voluntary motor control, commonly seen in patients taking antipsychotic drugs. EPSE’s include dystonias, parkinsonism, akathisia, and tardive dyskinesia. They can be frightening and uncomfortable, leading to problems with non-compliance and can even be life-threatening in the case of laryngeal dystonia. EPSE’s are thought to be due to antagonism of dopaminergic D2 receptors in the basal ganglia. Symptoms generally occur within the first few days of treatment, with dystonias appearing quickly, within a few hours of administration of the first dose. Newer antipsychotics tend to produce less EPSE’s, with clozapine carrying the lowest risk and haloperidol carrying the highest risk. Akathisia is the most resistant EPSE to treat. EPSE’s can also occur when antipsychotics are discontinued (withdrawal dystonia).

A limitation of the ACE-III is that it does not have a dedicated assessment for evaluating reasoning and decision-making abilities.

The Addenbrooke’s Cognitive Exam: A Brief Screening Tool for Dementia

The Addenbrooke’s cognitive examination (ACE) is a cognitive screening tool developed to detect dementia and differentiate Alzheimer’s dementia from frontotemporal dementia. It was created to address the limitations of the MMSE, which lacked sensitivity for frontal-executive dysfunction and visuospatial defects. The ACE is a brief test that takes 15-20 minutes to administer and is divided into five domains: attention and orientation, memory, verbal fluency, language, and visuospatial abilities. The total score is based on a maximum score of 100, with higher scores indicating better cognitive functioning.

The ACE has been shown to be a valid tool for detecting dementia, with two cut-off points often used depending on the required sensitivity and specificity. A score of less than 88 has 100% sensitivity for detecting dementia, while a score of less than 82 has 93% sensitivity and 100% specificity. It has also been useful in differentiating dementia from pseudo dementia and detecting cognitive impairment in atypical Parkinson syndromes. However, while the test has shown 100% sensitivity and specificity in studies, its performance may vary in clinical practice.